New Anticonvulsants: A Review of Applications for the Management of Substance Abuse Disorders

References

• Hobbs WR, Rail TW, Verdoorn TA: Hypnotics and sedatives: Ethanol. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. New York: McGraw-Hill; 1996
   Google Scholar
• Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L: A summary of mechanistic hypothesis of gabapentin pharmacology. Epilepsy Res 1998; 29:233–249
   PubMed Web of Science ®Google Scholar
• Myrick H, Henderson S, Brady K, Malcolm R: Gabapentin in the treatment of cocaine dependence: A case series. J Clin Psychiatry 2001; 62:19–23
   PubMed Web of Science ®Google Scholar
• Magnus L: Nonepileptic uses of gabapentin. Epilepsia 1999; 40(Suppl 6):S66–S72
   Google Scholar
• Sabers A, Gram L: Newer anticonvulsants: Comparative review of drug interactions adverse effects. Drugs 2000; 60:23–33
   PubMed Web of Science ®Google Scholar
• Willmore LJ: Choice and use of newer anticonvulsant drugs in older patients. Drugs Aging 2000; 17:441–452
   PubMed Web of Science ®Google Scholar
• Anonymous: Physicians Desk Reference 2002. Montvale: Medical Economics Company; 2002
   Google Scholar
• Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M: Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry 1999; 32:107–109
   PubMed Web of Science ®Google Scholar
• Watson WP, Robinson E, Little HJ: The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. Neuropharma-cology 1997; 36:1369–1375
   PubMed Web of Science ®Google Scholar
• Bailey CP, Molleman A, Little HJ: Comparison of the ef-fects of drugs on hyperexcitability induced in hippocampal slices by withdrawal from chronic ethanol consumption. Br J Pharmacol 1998; 123:215–222
   PubMed Web of Science ®Google Scholar
• Malcolm R, Myrick H, Brady K, Ballenger J: Update on an-ticonvulsants for the treatment of alcohol withdrawal. Am .1 Addict 2001; 10(Suppl):16–23
   Google Scholar
• Myrick H, Malcolm R, Brady K: Gabapentin treatment of al-cohol withdrawal. Am J Psychiatry 1998; 155:1626
   Google Scholar
• Jefferson JM: Benzodiazepines and anticonvulsants for the so-cial phobia (social anxiety disorder). J Clin Psychiatry 2001; 62(Suppl 1):50–53
   Google Scholar
• Van Ameringen M, Mancini C:Pharmacotherapy of social anx-iety disorder at the turn of the millenium. Psychiatr Clin North Am 2001; 24:783–803
   PubMed Web of Science ®Google Scholar
• Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, GreistJH, Sutherland SM: Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999; 19:341–348
   PubMed Web of Science ®Google Scholar
• Blanco C, Antia SX, Liebowitz MR: Pharmacotherapy of so-cial anxiety disorder. Biol Psychiatry 2002; 51:109–120
   PubMed Web of Science ®Google Scholar
• Chatterjee C, Ringold A: A case report of reduction in al-cohol craving and protection against alcohol withdrawal by gabapentin. J Clin Psychiatry 1999; 60:617
   PubMed Web of Science ®Google Scholar
• Hamner MB, Brodrick PS, Labbate LA: Gabapentin in PTSD: A retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001; 13:141–146
   PubMedGoogle Scholar
• Vieta E, Martinez-Aran A, Nieto E, Colom F, Reinares M, Benabarre A, Gasto C: Adjunctive gabapentin treatment of bipolar disorder. Eur Psychiatry 2000; 15:433–437
   PubMed Web of Science ®Google Scholar
• Yasmin S, Carpenter LL, Leon Z, Siniscalchi JM, Price LH: Adjunctive gabapentin in treatment-resistant depression: A retrospective chart review. J Affect Disord 2001; 63:243–247
   PubMed Web of Science ®Google Scholar
• Karam-Hage M, Brower K: Gabapentin treatment for insom-nia associated with alcohol dependence. Am J Psychiatry 2000; 157:151
   PubMed Web of Science ®Google Scholar
• Withers NW, Pulvirenti L, Koob GF, Gillin JC: Cocaine abuse and dependence. J Clin Psychopharmacol 1995; 15:63–78
   PubMedGoogle Scholar
• Raby WN: Gabapentin therapy for cocaine cravings. Am J Psy-chiatry 2000; 157:12
   Google Scholar
• Markowitz J, Finkenbine R, Myrick H: Gabapentin abuse in a cocaine user: Implications for treatment. J Clin Psychophar-macol 1997; 17:423–424
   PubMed Web of Science ®Google Scholar
• de-Paris F, Brusnello JV, Vianna MR, Salgueiro JB, Quevedo J, Izquierdo I, Kapczinski F: The anticonvulsant compound gabapentin posses anxiolytic but not amnestic effects in rats. Behav Pharmacol 2000; 11:169–173
   Google Scholar
• Gasior M, Ungard J, Witkin J: Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures. J Pharmacol Exp Ther 1999; 290:1148–1156
   PubMed Web of Science ®Google Scholar
• Lado FA, Sperber EF, Moshe SL: Anticonvulsant efficacy of gabapentin on kindling in the immature brain. Epilepsia 2001; 42:458–463
   PubMedGoogle Scholar
• Dam M, Ekberg R, LOyning Y, Waltimo O, Jakobsen K: A double-blind study comparing oxcarbazepine and carba-mazepine in patients with newly diagnosed, previously un-treated epilepsy. Epilepsy Res 1989; 3:70–76
   PubMed Web of Science ®Google Scholar
• Reinikainen KJ, Keränen T, Halonen T, Komulainen H, Riekkinen PJ: Comparison of oxcarbazepine and carba-mazepine: A double-blind study. Epilepsy Res 1987; 1:284–289
   PubMed Web of Science ®Google Scholar
• Wamil AW, Portet Ch, Jensen PK, Schmutz M, McLean MJ: Oxcarbazepine and its monohydroxy metabolite limit action potential firing by mouse central neurons in cell culture. Epilepsia 1991; 32(Suppl 3):65–66
   Google Scholar
• Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR: Oxcarbazepine: Preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 1994; 35(Suppl 5): S47–S50
   Google Scholar
• Faigle JW, Menge GP: Pharmacokinetic and metabolic fea-tures of oxcarbazepine and their clinical significance: Com-parison with carbamazepine. Int Clin Psychopharmacol 1990; 5:73–82
   Google Scholar
• Klitgaard NA, Kristensen 0: Use of saliva for monitoring ox-carbazepine therapy in epileptic patients. EurJ Clin Pharmacol 1986; 31:91–94
   Google Scholar
• Patsalos PN, Elyas AA, Zakrzewska JM: Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepin e, in patients with trigeminal neuralgia. Eur J Clin Pharmacol 1990; 39:413–455
   PubMed Web of Science ®Google Scholar
• Degen PH, Flesch G, Cardot JM, Czendlik C, Dieterle W: The influence of food on the disposition of the antiepileptic ox-carbazepine and its major metabolites in healthy volunteers. Biopharm Drug Dispos 1994; 15:519–526
   PubMed Web of Science ®Google Scholar
• Larkin JG, McKee PJW, Forrest G, Beastall GH, Park BK, Lowrie JI, Lloyd P, Brodie MJ: Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 1991; 31:65–71
   PubMed Web of Science ®Google Scholar
• Rouan MC, Lecaillon JB, Godbillon J, Menard F, Darragon T, Meyer P, Kourilsky O, Hillion D, Aldigier IC, Jungers P: The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Pharmacol 1994; 47:161–167
   Google Scholar
• van Heiningen PNM, Eve MD, Oosterhuis B, Jon kman JHG, de Bruin H, Hulsman JARJ, Richens S, Klosterskov Jensen P: The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 4:410–419
   Google Scholar
• Keranen T, Jolkkonen J, Jensen PK, Menge GP, Anders-son P: Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand 1992; 86:120–123
   PubMed Web of Science ®Google Scholar
• Keranen T, Jolkkonen J, Klosterskov-Jensen P, Menge GP: Ox-carbazepine does not interact with cimetidine in healthy vol-unteers. Acta Neurol Scand 1992; 85:239–242
   PubMed Web of Science ®Google Scholar
• Sonnen AEH: Oxcarbazepine and oral contraceptives. Acta Neurol Scand 82\(Suppl 133):37
   Google Scholar
• Kramer G: Oxcarbazepine-verapamil drug interactions in healthy volunteers. Epilepsia 1991; 32(Suppl 1):70–71
   Google Scholar
• Zaccara G, Gangemi PF, Bandoni L, Menge GP, Monza GC: Evaluation of the influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Epilepsia 1991; 32(Suppl 1):71
   Google Scholar
• Steinhoff BJ: Hyponatremic coma under oxcarbazepine ther-apy. Epilepsy Res 1992; 11:67–70
   PubMed Web of Science ®Google Scholar
• Malcolm R, Ballenger JC, Sturgis ET, Anton R: Double-blind controlled trial comparing carbamazepine to oxazepam treat-ment of alcohol withdrawal. Am J Psychiatry 1989; 146:617–621
   PubMed Web of Science ®Google Scholar
• Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC: The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med 2002; 17:1–7
   PubMedGoogle Scholar
• Stuppaeck CH, Pycha R, Whitworth AB, Oberbauer H, Fleischhacker WW: Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: A double-blind study. Alco-hol Alcohol 1992; 27:153–158
   PubMed Web of Science ®Google Scholar
• Ries RK, Roy-Byrne PP, Ward NG, Neppe V, Cullison S: Carbamazepine treatment for benzodiazepine withdrawal. Am J Psychiatry 1989; 146:536–537
   PubMedGoogle Scholar
• Schweizer E, Rickels K, Case WG, Greenblatt DJ: Car-bamazepine treatment in patients discontinuing long-term benzodiazepine therapy: Effects on withdrawal severity and outcome. Arch Gen Psychiatry 1991; 48:448–452
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Post RM: Kindling as a model for alcohol with-drawal syndromes. Br J Psychiatry 1978; 133:1–14
   PubMed Web of Science ®Google Scholar
• Schmutz M, Klebs K, Baltzer V: Inhibition or enhancement of kindling evolution by antiepileptics. J Neural Transm 1988; 72:245–257
   PubMedGoogle Scholar
• Windhaber J, Maierhofer D, Dantendorfer K: Oxcarbazepine for panic disorder occurring after two grand mal seizures: A case report. J Clin Psychiatry 1997; 58:404–405
   Google Scholar
• Emrich HM, Altmann H, Dose M, von Zerssen D: Therapeutic effects of GABA-ergic drugs in affective disorders: A prelim-inary report. Pharmacol Biochem Behav 1983; 19:369–372
   PubMed Web of Science ®Google Scholar
• Beijamini V, Skalisz LL, Joca SRL, Andreatini R: The effect of oxcarbazepine on behavioural despair and learned helpless-ness. Eur J Pharmacol 1998; 347:23–27
   PubMed Web of Science ®Google Scholar
• Huber TJ, Nickel V, Trfiger M, Schneider U, Husstedt J, Emrich HM: A syndrome of psychosis following discontinuation of an estrogen-progestogen contraceptive and improvement fol-lowing replacement: A case report. Neuropsychobiology 1999; 40:75–77
   PubMed Web of Science ®Google Scholar
• Dose M, Apelt S, Emrich HM: Carbamazepine as an adjunct of an tipsychotic therapy. Psychiatry Res 1987; 22:303–310
   PubMed Web of Science ®Google Scholar
• Hernandez-Avila CA, Ortega-Soto HA, Jasso A, Hasfura-Buenaga CA, Kranzler HR: Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol. Psychiatr Serv 1998; 49:812–815
   PubMed Web of Science ®Google Scholar
• Mueller TI, Stout RL, Rudden S, Brown RA, Gordon A, Solomon DA, Recupero PR: A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res 1997; 21:86–92
   PubMed Web of Science ®Google Scholar
• Stuppaeck CH, Whitworth AB, Fleischhacker WW: Abuse po-tential of carbamazepine. J Nerv Ment Dis 1993; 181:519–520
   Google Scholar
• Christensen J, Balslev T, Villadsen J, Heinsvig EM, Dam M, Paulsen JH: Removal of 10-Hydroxycarbazepine by plasma-pheresis. Ther Drug Monit 2001; 23:374–379
   Google Scholar
• Meldrum BS, Chapman AG: Basic mechanisms of Gabitril (tiagabine) and future potential developments. Epilepsia 1999; 40(Suppl 9):S2–S6
   Google Scholar
• Borden LA: GABA transporter heterogeneity: Pharmacology and cellular localization. Neurochem lot 1996; 29:335–356
   PubMed Web of Science ®Google Scholar
• Schachter SC: A review of the antiepileptic drug tiagabine. Clin Neuropharmacol 1999; 22:312–317.
   PubMed Web of Science ®Google Scholar
• Schachter SC: Tiagabine. Epilepsia 1999; 40 (Supp15):S17–S22
   Google Scholar
• Gustayson LE, Mengel HB: Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995; 36:605–611
   Google Scholar
• Gustayson LE, Boellner SW, Granneman GR, Qian JX, Guen-ther HJ, el-Shourbagy T, Sommerville KW: A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology 1997; 48:1032–1037
   Google Scholar
• Cato A III, Gustayson LE, Qian J, El-Shourbagy T, Kelly EA: Effect of renal impairment on the pharmacokinetics and tol-erability of tiagabine. Epilepsia 1998; 39:43–47
   Google Scholar
• Gustayson LE, Cato A III, Boellner SW, Guoliang SC, Jiang XQ, Guenther HJ, Sommerville KW: Lack of pharmacoki-netic drug interactions between tiagabine and carbamazepine or phenytoin. Am J Ther 1998; 5:9–16
   Google Scholar
• Gustayson LE, Sommerville KW, Boellner SW, Witt GF, Guenther HJ, Granneman GR: Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and val-proate. Am J Ther 1998; 5:73–79
   Google Scholar
• Richens A, Marshall RW, Dirach J, Jansen JA, Snel S, Pedersen PC: Absence of interaction between tiagabine, a new antiepileptic drug, and the benzodiazepine triazolam. Drug Metabol Drug Interact 1998; 14:159–177
   Google Scholar
• Wilbur K, Ensom MH: Pharmacokinetic drug interactions be-tween oral contraceptives and second generation anticonvul-sants. Clin Pharmacokinet 2000; 38:355–365
   PubMed Web of Science ®Google Scholar
• Samara EE, Gustayson LE, El-Shourbagy T, Locke C, Granneman GR, Sommerville KW: Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy. Epilepsia 1998; 39:868–873
   PubMedGoogle Scholar
• Sveinbjornsdottir S, Sander JW, Patsalos PN, Upton D, Thompson PJ, Duncan JS: Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994; 3:29–35
   PubMedGoogle Scholar
• Dodrill CB, Arnett JL, Sommerville KW, Shu V: Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997; 48:1025–1031
   Google Scholar
• Dodrill CB, Arnett JL, Shu V, Pixton GC, Lenz GT, Sommerville KW: Effects of tiagabine monotherapy on abili-ties, adjustment, and mood. Epilepsia 1998; 39:33–42
   PubMedGoogle Scholar
• Hogan RE, Bertrand ME, Deaton RL, Sommerville KW: Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. Epilepsy Res 2000; 41:23–28
   PubMedGoogle Scholar
• Loiseau P: Review of controlled trials of gabatril (tiagabine): A clinician's viewpoint. Epilepsia 1999; 40 (Suppl 9):S14–S19
   Google Scholar
• Booth BM, Blow FC: The kindling hypothesis: Further evi-dence from a U.S. national study of alcoholic men. Alcohol Alcohol 1993; 28:593–598
   PubMed Web of Science ®Google Scholar
• Brown ME, Anton RF, Malcolm R, Ballenger JC: Alcohol detoxification and withdrawal seizures: Clinical support for a kindling hypothesis. Biol Psychiatry 1998; 23:507–514
   Google Scholar
• Gross MM, Rosendlatt SM, Lewis E, Chartoff S, Malenowski B: Acute alcoholic psychoses and related syndromes: Psy-chosocial and clinical characteristics and their implications. Br J Addict Alcohol Other Drugs 1972; 67:15–31
   Google Scholar
• Lechtenberg R, Worner TM: Seizure risk with recurrent alco-hol detoxification. Arch Neurol 1990; 47:535–538
   Google Scholar
• Lechtenberg R, Worner TM: Relative kindling effect of detox-ification and non-detoxification admissions in alcoholics. Al-cohol Alcohol 1991; 26:221–225
   PubMed Web of Science ®Google Scholar
• Lechtenberg R, Worner TM: Total ethanol consumption as a seizure risk factor in alcoholics. Acta Neurol Scand 1992; 85:90–94
   Google Scholar
• Shaw GK, Waller S, Latham CJ, Dunn G, Thomson AD: The detoxification of alcoholic in-patients and predictors of out-come. Alcohol Alcohol 1998; 33:291–303
   PubMedGoogle Scholar
• Malcolm R, Roberts JS, Wang W, Myrick H, Anton RF: Mul-tiple previous detoxifications are associated with less response and heavier drinking during an index outpatient detoxification. Alcohol 2000; 22:159–164
   PubMed Web of Science ®Google Scholar
• Worner TM: Relative kindling effect of readmissions in alco-holics. Alcohol Alcohol 1996; 31:375–380
   Google Scholar
• Wojnar M, Bizon Z, Wasilewski D: Assessment of the role of kindling in the pathogenesis of alcohol withdrawal seizures and delirium tremens. Alcohol Clin Exp Res 1999; 23:204–208
   PubMed Web of Science ®Google Scholar
• Cleton A, Altorf BA, Voskuyl RA, Danhof M: Effect of amygdala kindling on the central nervous system effects of tiagabine: EEG effects versus brain GABA levels. Br J Pharmacol 2000; 130:1037–1044
   Google Scholar
• Schmitt U, Hiemke C: Effects of GABA-transporter (GAT) inhibitors in rat behaviour in open-field and elevated plus-maze. Behav Pharmacol 1999; 10:131–137
   PubMed Web of Science ®Google Scholar
• Leppik IE: Tiagabine: The safety landscape. Epilepsia 1995; 36(Suppl 6) S10–513
   PubMed Web of Science ®Google Scholar
• Zwanzger P, Baghai T, Schule C, Minov C, Padberg F, Moller HJ, Rupprecht R: Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry 2001; 62:656–657
   PubMed Web of Science ®Google Scholar
• Kastberg H, Jansen JA, Cole G, Wesnes K: Tiagabine: Absence of kinetic or dynamic interactions with ethanol. Drug Metabol Drug Interact 1998; 14:259–273
   PubMedGoogle Scholar
• Tremont-Lukats IW, Megeff C, Backonja MM: Anticonvul-sants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs 2000; 60:1029–1052
   PubMed Web of Science ®Google Scholar
• Gerasimov MR, Schiffer WK, Brodie JD, Lennon IC, Taylor SJ, Dewey SL: Gamma-aminobutyric acid mimetic drugs dif-ferentially inhibit the dopamine reponse to cocaine. Fur J Pharmacol 2000; 395:129–135
   Google Scholar
• Winhusen T, Somoza E, Goldsmith J, Dingal B, Harrer J, Mezinskis J, Coleman F, Elkashef A, Montgomery A, Leiderman D, Berger SP: A NIDA-sponsored clinical rapid efficacy screening trial (CREST) of tiagabine, sertraline, and donepezil. Drug Alcohol Depend 2001; 63(Suppl 1): S170–S171
   Google Scholar
• Lancel M, Faulhaber 1, Deisz RA: Effect of the GABA reup-take inhibitor tiagabine on sleep and EEG power spectra in the rat. Br J Pharmacol 1998; 123:1417–1477
   Google Scholar
• Lands WE: Alcohol, slow wave sleep, and the somatotropic axis. Alcohol 1999; 18:109–122
   PubMed Web of Science ®Google Scholar
• Mathias S, Wetter TC, Steiger A, Lance] M: The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging 2001; 22:247–253
   PubMed Web of Science ®Google Scholar